Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

“When we launch, we’ll go all in,” Novo’s Executive Vice President for International Operations, Emil Kongshøj Larsen, told CNBC in an interview on Tuesday. “It’s a major opportunity.” $NVO is preparing launch of wegovy pill outside US in several countries. Likely start early to mid Q3 NVO is also shaping the expectations. While they believe wegovy pill can be a big product outside US, they do caution people from expecting the same very steep sales curve. In US wegovy pill is significantly lower prices for start doses than wegovy pen. Even though NVO has not revealed pricing structure outside US yet, it’s clear that we should not expect to see the same repeated outside US. Price will likely be about the same as wegovy pen. And therefore it will not open the market further with lower prices as seen in US. Germany, UK, Norway, Denmark and Spain could likely be in the first wave of launch in Europe $LLY $VKTX

Also bei uns in DK ist sie bei -3%.......

Und wieder hast du falsch gelegen.

Schlecht gealtert. Leg dich wieder hin.

https://www.boerse-express.com/news/articles/novo-nordisk-aktie-207000-wegovy-rezepte-woechentlich-906285

Heute wird ein großartiger Tag ☝🏻

Hä? Steigt doch.

Das ist von heute. Eco war letzte woche

Gleich wieder 46$

... das ist aber auch schon ne Woche alt

$NVO $NOVO SB1 Markets reiterates its Buy rating on Novo Nordisk with a target price of DKK 350 after both Novo and Eli Lilly have presented news at the European Congress on Obesity (ECO 2026) in Istanbul. SB1 Markets says the data shows that a large proportion of the total weight loss is linked to early high responders, and this group appears to account for 20–30 percent of users. In Novo's STEP UP study, 84 percent of the weight loss was related to fat loss. In Lilly's study, SB1 Markets notes that patients using Wegovy maintained their weight better after switching to oral treatment compared to users of Zepbound. This is also interesting in light of the fact that Novo's oral drug shows almost 50 percent higher weight loss effect compared to Lilly's weight loss tablet (16.6 percent vs. 11.2 percent). Around 70-75 percent of users are expected to be normal responders. In this group, the difference between injectable and oral alternatives is significantly smaller compared to high responders: around 3.9 percent vs. 6.1 percent. These dynamics may lead to a trend in the future where normal responders switch to oral alternatives earlier, possibly after the first 4-6 months of injection treatment, SB1 Markets says. SB1 Markets also notes that a very high proportion of users at this stage of the launch of Novo Nordisk's Oral Wegovy (January to early May) are new to obesity treatment. This clearly indicates that Lilly's and Novo's oral drugs are likely to accelerate penetration in the US obesity market.

Endlich macht Novo wieder das, was es am besten kann. Fallen ohne Ende

Bin gespannt wie es losgeht. Wir haben ein riesen gap!

30 ist um Anflug

Nein, aber schön ist es trotzdem nicht. Aktuell ist mein Depot eine Wundertüte.

Ist was passiert? Hab ich etwas verpasst?